Greenwich LifeSciences, Inc.

NASDAQ:GLSI

Biotechnology

Healthcare
$20.58 -3.08%

-$0.74 today

Market cap
$302.08M
Beta
1.38
P/E (TTM)
-15.6
EPS (TTM)
-$1.49
52W Low $7.78High $34.10

Volume 0.71M

Average 0.14M

GLSI Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Greenwich LifeSciences, Inc.NASDAQ: GLSI

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income growth accelerates

Q1 FY2026 net income of $5.66M (cash outflow) rose 73.6% year over year, ahead of the +31.3% change in trailing-twelve-month net income. Sequentially, it fell 28.6% from the prior quarter. Over 3 fiscal years it compounded at +35.2% a year.

Context

  • Net income grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate of -$18.27M (-5.6%) for the fiscal year ending Dec 2026, a slowdown from the +22.6% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$5.66M-28.6% QoQ
Last fiscal yearDec 2025
-$19.36M+22.6% YoY
LTMMar 2026
-$21.76M+31.3% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+73.6%+21.2%-52.4 pp
1 year+22.6%-5.6%-28.2 pp
3-year CAGR+35.2%——
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(19.36M) USD
Year-over-year change
-22.6%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How GLSI compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +31.3% is the 5th highest of 8, against a peer median of +67.3%.
  • Over three fiscal years its annual growth of +35.2% compares with a peer median of +16.7%.
GLSI Competitors
Net Income for GLSI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SRZNSurrozen, Inc.LTM Mar 2026$342.56M USD+319.3%+88.7%4571.1%
IRDOpus Genetics, Inc.LTM Mar 2026$106.93M USD+82.4%—892.4%
SEERSeer, Inc.LTM Mar 2026$70.49M USD-17.9%-7.5%468.7%
AGENAgenus Inc.LTM Mar 2026$62.51M USD+132.2%+0.2%50.5%
ONCYOncolytics Biotech Inc.LTM Mar 2026CA$35.52M CAD+12.8%+16.7%—
IMMXImmix Biopharma, Inc.LTM Mar 2026$34.98M USD+67.3%+52.9%—
HURATuHURA Biosciences, Inc.LTM Mar 2026$30.92M USD—+47.5%—
GLSIGreenwich LifeSciences, Inc.LTM Mar 2026$21.76M USD+31.3%+35.2%—
CGTXCognition Therapeutics, Inc.LTM Mar 2026$19.58M USD-41.2%+3.2%—
Peer median (excluding GLSI) —+67.3%+16.7%680.6%

Competitors are the stored peer set for GLSI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(4.57M)(7.83M)(8.89M)(15.79M)(19.36M)
Depreciation & Amortization3.61K3.61K3.61K3.61K1.78K
Deferred Income Tax(1.19M)(1.75M)000
Stock-Based Compensation660.58K1.74M2.38M7.25M6.8M
Change in Working Capital(385.17K)(122.27K)31.5K1.27M2.64M
Accounts Receivables00000
Inventory00000
Accounts Payables(526.73K)035.47K921.22K2.07M
Other Working Capital141.57K(122.27K)(3.97K)344.11K568.12K
Other Non-Cash Items1.19M1.75M000
Operating Cash Flow(4.29M)(6.2M)(6.48M)(7.27M)(9.91M)
Capital Expenditures0(3)033
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow00000
Debt Repayment00000
Common Stock Issued3.11M004.37M12M
Common Stock Repurchased0(7.54M)000
Dividends Paid00000
Other Financing Activities(275.15K)0000
Financing Cash Flow2.84M(7.54M)04.37M12M
Effect of Forex Changes00000
Net Change in Cash(1.46M)(13.74M)(6.48M)(2.9M)2.09M
Free Cash Flow(4.29M)(6.2M)(6.48M)(7.27M)(9.91M)

Greenwich LifeSciences, Inc.

NASDAQ:GLSI

Intrinsic Alpha fair value

Locked

Current Price

$20.58

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.